Cargando…
Diabetic retinopathy: could the alpha-1 antitrypsin be a therapeutic option?
Diabetic retinopathy is one of the most important causes of blindness. The underlying mechanisms of this disease include inflammatory changes and remodeling processes of the extracellular-matrix (ECM) leading to pericyte and vascular endothelial cell damage that affects the retinal circulation. In t...
Autores principales: | Ortiz, Gustavo, Salica, Juan P, Chuluyan, Eduardo H, Gallo, Juan E |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4335423/ https://www.ncbi.nlm.nih.gov/pubmed/25723058 http://dx.doi.org/10.1186/0717-6287-47-58 |
Ejemplares similares
-
Elucidating the mechanism of action of alpha-1-antitrypsin using retinal pigment epithelium cells exposed to high glucose. Potential use in diabetic retinopathy
por: Potilinski, María Constanza, et al.
Publicado: (2020) -
Selective decrease in alpha(1)-antitrypsin levels in diabetic retinopathy: Could the levels of it be playing a role in the pathophysiology of diabetic retinopathy?
por: Kunder, Mamatha, et al.
Publicado: (2022) -
Transglutaminase binding fusion protein linked to SLPI reduced corneal inflammation and neovascularization
por: Salica, Juan P, et al.
Publicado: (2015) -
Alpha-1 Antitrypsin as a Therapeutic Agent for Conditions not Associated with Alpha-1 Antitrypsin Deficiency
por: Wanner, Adam
Publicado: (2015) -
Hypothesis: Alpha-1-antitrypsin is a promising treatment option for COVID-19
por: Bai, Xiyuan, et al.
Publicado: (2021)